<?xml version="1.0" encoding="UTF-8"?>
<Bundle xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://hl7.org/fhir definitions-2/fhir-all-xsd/fhir-all.xsd"
    xmlns="http://hl7.org/fhir">
    <!-- Bundle for Package Leaflet -->
    <id value="d1a125cf-b46c-40cf-82cf-5b754eb0f19e"/><!-- PIL OTC Norwegian -->
    <meta>
        <versionId value="1"/>
        <!-- Document version id -->
        <lastUpdated value="2021-09-06T20:34:02.697+00:00"/>
        <!-- date this version was finalized -->
    </meta>
    <identifier>
        <!-- unique id assigned to the regulated document -->
        <system value="http://ema.europa.eu/fhir/identifier/documentid"/>
        <value value="ff41bd8d-8cac-4410-bfa5-b8120002fecf"/>
    </identifier>
    <type value="document"/>
    <timestamp value="2021-09-06T20:34:02.697+00:00"/>
    <!-- date of initial approval for this ePI -->
    <entry>
        <fullUrl value="ed1e7d6f-f702-499c-84e9-892cee496751"/>
        <!-- UUID for this resource -->
        <resource>
            <Composition>
                <!-- Composition holds the narrative text of the ePI (e.g., paragraphs, tables, bulleted lists) -->
                <language value="no"/>
                <contained>
                    <Binary>
                        <id value="nasal"/>
                        <contentType value="image/png"/>
                        <data                          value="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"
                        />
                    </Binary>
                </contained>
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                    <valueReference>
                        <reference value="#stylesheet0"/>
                        <!-- Stylesheet reference -->
                    </valueReference>
                </extension>
                <status value="final"/>
                <!-- preliminary | final | amended | entered-in-error -->
                <type>
                    <!-- ePI Type -->
                    <coding>
                        <system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
                        <code value="100000155538"/>
                        <display value="B. PAKNINGSVEDLEGG"/>
                    </coding>
                </type>
                <subject>
                    <reference value="http://spor.ema.europa.eu/v2/MedicinalProductDefinition"/>
                    <!-- Reference to Medicinal Product Definition resource -->
                    <identifier>
                        <!-- Market Authorization Number (MAN) -->
                        <system value="http://spor.ema.europa.eu/v2/marketing-authorisation-numbers"/>
                        <value value="PL 16028/0049"/>
                    </identifier>
                </subject>
                <date value="2021-09-06T20:34:02.697+00:00"/>
                <!-- Last modified date for this composition -->
                <author>
                    <!-- Market Authorization Holder (MAH) ID -->
                    <identifier>
                        <system value="http://spor.ema.europa.eu/v1/100000000005"/>
                        <value value="5678"/>
                    </identifier>
                </author>
                <title
                    value="BARE TEST FORMÅL -  PAKNINGSVEDLEGG Acme Dekongestant 0,05% m/v nesespray (oksymetazolinHydroklorid)"/>
                <!-- Human Readable name/title for this ePI -->
                <section id="d52d35f5-2432-45c6-9e35-18870918d379">
                    <title
                        value="Les hele dette pakningsvedlegget nøye før du begynner å bruke dette legemidletinneholder viktig informasjon for deg."/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="1"/>
                            <display
                                value="Les hele dette pakningsvedlegget nøye før du begynner å bruke dette legemidletinneholder viktig informasjon for deg."
                            />
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p> Ta alltid dette legemidlet nøyaktig som beskrevet i dette pakningsvedlegget eller som legen din eller apotekethar fortalt deg.</p>
                            <ul>
                                <li>Oppbevar dette pakningsvedlegget. Du må kanskje lese den igjen.</li>
                                <li>Spør apoteket hvis du trenger mer informasjon eller råd.</li>
                                <li>Snakk med legen din eller apoteket dersom du får bivirkninger. Dette inkluderer eventuelle bivirkninger som ikke er nevnt i dette pakningsvedlegget. Se avsnitt 4.</li>
                                <li>Du må snakke med lege hvis du ikke føler deg bedre eller hvis du føler deg verre etter 7 dager.</li>
                            </ul>
                        </div>
                    </text>
                </section>
                <section id="1a76ca9a-b2c5-4712-8495-c3322e9dac1d">
                    <title value="Hva står i dette pakningsvedlegget:"/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="2"/>
                            <display value="Hva står i dette pakningsvedlegget:"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <ol>
                                <li><b>Hva Decongestant Nasal Spray er og hva det brukes mot </b></li>
                                <li><b>Hva du trenger å vite før du bruker Decongestant Nasal Spray </b></li>
                                <li><b>Hvordan bruke Decongestant Nasal Spray </b></li>
                                <li><b>Mulige bivirkninger </b></li>
                                <li><b>Hvordan du oppbevarer Decongestant Nasal Spray </b></li>
                                <li><b>Innhold av pakningen og ytterligere informasjon</b></li>
                            </ol>
                        </div>
                    </text>
                </section>
                <section id="a511f047-1403-4e23-b7e2-212d0310dc5b">
                    <title value="1. Hva Decongestant Nasal Spray er og hva det brukes til"/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="3"/>
                            <display
                                value="1. Hva Decongestant Nasal Spray er og hva det brukes til"
                            />
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>Denne nesesprayen inneholder oksymetazolinhydroklorid, som er et avsvannende middel. Det lindreren tett, blokkert nese ved å krympe blodårene som hjelper til med å åpne nesegangene. Denvirker i løpet av få minutter og varer i opptil 12 timer.Medisinen er en løsning som sprøytes inn i neseborene for å lindre overbelastningnese og bihuler som du får under forhold som forkjølelse, katar og høysnue.</p>
                        </div>
                    </text>
                </section>
                <section id="da7a3487-d88d-4dee-9049-b5242309d47e">
                    <title value="2. Hva du trenger å vite før du bruker Decongestant Nasal Spray"/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="4"/>
                            <display
                                value="2. Hva du trenger å vite før du bruker Decongestant Nasal Spray"
                            />
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p><b>Ikke bruk denne nesesprayen hvis du:</b></p>
                            <ul>
                                <li>er allergisk mot oksymetazolin eller noen av de andre ingrediensene i dette legemidlet (listet opp i avsnitt 6)</li>
                                <li>hhar feokromocytom (en sjelden svulst i binyrene)</li>
                                <li>har blitt operert for å fjerne hypofysen eller du nylig har operert nesen eller bihulene.</li>
                                <li>tar allerede medisiner for å blokkere nesen din</li>
                                <li>har betent hud eller slimhinner i neseborene eller har skorper i nesen</li>
                            </ul>
                            <p><b>Ikke gi denne nesesprayen til barn under 12 år</b></p>
                            <br/>
                            <p><b>Advarsler og forholdsregler</b></p>
                            <br/>
                            <p><b>Snakk med legen din eller apoteket før du bruker denne nesesprayen hvis du:</b></p>
                            <ul>
                                <li>har problemer med prostata</li>
                                <li>er eldre</li>
                                <li>har glaukom (økt trykk i øyet)</li>
                                <li>har koronar hjertesykdom, hjerte -astma eller annen hjertesykdom</li>
                                <li>har høyt blodtrykk</li>
                                <li>har en overaktiv skjoldbruskkjertel eller andre problemer med skjoldbruskkjertelen</li>
                                <li>har diabetes</li>
                                <li>har nyre- eller leverproblemer</li>
                            </ul>
                            <p><b>Hvis noe av det følgende skjer, bør denne nesesprayen stoppes:</b></p>
                            <ul>
                                <li>hallusinasjoner</li>
                                <li>rastløshet</li>
                                <li>søvnforstyrrelser</li>
                            </ul>
                            <p><b>Holdes vekk fra øynene.</b></p>
                            <br/>
                            <p><b>Andre legemidler og decongestant nesespray</b></p>
                            <p>Fortell legen din eller apoteket dersom du bruker eller bruker, eller nylig har brukt eller bruker andre legemidler:</p>
                            <ul>
                                <li>Ikke bruk hvis du tar eller nylig har tatt monoaminoxidasehemmere (se ovenfor)</li>
                                <li>Ikke bruk hvis du bruker betablokkere, da effekten kan reduseres</li>
                                <li>Trisykliske antidepressiva (legemidler som brukes til behandling av depresjon som amitriptylin og imipramin)</li>
                                <li>Medisiner mot høyt blodtrykk (for eksempel bethanidin, debrisoquine og guanethidine), da virkningen kan reduseres</li>
                                <li>Parkinsons sykdom (bromokriptin og rasagilin) ​​behandling kan påvirkes hvis den brukes samtidig</li>
                                <li>Digoksin eller digitoksin for hjertesvikt, da det kan forårsake uregelmessig hjerterytme (dysrytmier) hvis det tas samtidig</li>
                                <li>Ergotamin eller metysergid for lindring av migrene</li>
                                <li>Medisiner eller kosttilskudd for å redusere appetitten eller gjøre deg mer våken (amfetaminlignende psykostimulerende midler)</li>
                                <li>Skjoldbruskhormoner f.eks. Levotyroksin</li>
                                <li>Oksytocin brukes til å hjelpe fødsel eller amming</li>
                            </ul>
                            <p><b>Graviditet og amming:</b></p>
                            <p><b>Ikke bruk</b> ihvis du er gravid. Snakk med legen din eller apoteket før du bruker nesesprayen hvis du ammer.</p>
                            <br/>
                            <p><b>Kjøring og bruk av maskiner</b></p>
                            <p>Det er ikke observert effekt på evnen til å kjøre bil eller bruke maskiner.</p>
                            <br/>
                            <p><b>Viktig informasjon om noen av ingrediensene i dette legemidlet</b></p>
                            <ul>
                                <li>Inneholder benzalkoniumklorid som kan forårsake irritasjon eller hevelse inne i nesen, spesielt hvis det brukes i lang tid.</li>
                                <li>Inneholder tiomersal som et konserveringsmiddel som kan forårsake lokale hudreaksjoner (f.eks. Kontaktdermatitt) og misfarging. Det kan også forårsake allergiske reaksjoner.</li>
                            </ul>
                            <p>Fortell legen din dersom du har noen allergier</p>
                        </div>
                    </text>
                </section>
                <section id="3b08696c-b145-47ed-9fec-6e10ac431f94">
                    <title value="3. Hvordan du bruker Decongestant Nasal Spray"/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="5"/>
                            <display value="3. Hvordan du bruker Decongestant Nasal Spray"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>Kun til nese</p>
                            <img src="#nasal" height="15%" width="25%"
                                alt="An image of spraying into nose"/>
                            <br/>
                            <br/>
                            <table>
                                <tbody>
                                    <tr>
                                        <th>Alder</th>
                                        <th>Dose og hvordan du bruker</th>
                                        <th>Hvor ofte skal det brukes</th>
                                    </tr>
                                </tbody>
                                <tbody>
                                    <tr>
                                        <td><b>Voksne, eldreog barn i alderen12 år og oppover</b></td>
                                        <td>
                                            <p>See diagram</p>
                                            <p>Fjern hetten. Hold beholderenoppreist, plasser tuppen av spraydysenbare inn i hvert nesebor. Hold det andre neseboretlukket. Klem beholderen lett<b>o ganger</b> mens du puster inn gjennom nesensamtidig. Gjenta for den andrenesebor. Tørk av neseapplikatoren med enrent, vått vev og sett på lokketumiddelbart etter søknaden.</p>
                                        </td>
                                        <td>Nesespraydosenkan brukes inntilto ganger daglig, eller brukt klsengetid for å gi lindringgjennom natten.</td>
                                    </tr>
                                    <tr>
                                        <td colspan="3"><b>Skal ikke brukes til barn under 12 år</b></td>
                                    </tr>
                                    <tr>
                                        <td colspan="3">
                                            <p>Ikke overskrid den angitte dosen.</p>
                                            <p><b>Ikke bruk kontinuerlig i mer enn 7 dager .</b></p>
                                            <p>Ikke bruk kontinuerlig i mer enn 7 dager .</p>
                                            <p>Dette produktet er ikke egnet for langvarig bruk (se også avsnitt 4 'Mulige bivirkninger').</p>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td colspan="3">Rådfør deg med lege hvis symptomene vedvarer.</td>
                                    </tr>
                                </tbody>
                            </table>
                            <br/>
                            <p><b>Hvis du bruker for mye:</b></p>
                            <p>Snakk med lege eller apotek hvis du har brukt mer spray enn angitt doseumiddelbart.</p>
                        </div>
                    </text>
                </section>
                <section id="1efef57d-8daf-4371-9760-90787a3754e0">
                    <title value="4. Mulige bivirkninger"/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="6"/>
                            <display value="4. Mulige bivirkninger"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>De fleste bruker denne nesesprayen uten problemer, men som alle medisiner kan den ha denbivirkninger</p>
                            <br/>
                            <p><b>Allergisk reaksjon</b></p>
                            <p><b>Slutt å bruke nesesprayen og kontakt legen din eller gå til nærmeste sykehuslegevakten umiddelbart hvis du merker:</b></p>
                            <ul>
                                <li>hudutslett eller kløe</li>
                                <li>nysing eller svie eller svie i nesen</li>
                                <li>hevelse i nese, lepper, tunge eller svelg</li>
                                <li>kortpustethet eller pustevansker</li>
                            </ul>
                            <p><b>Andre bivirkninger</b></p>
                            <ul>
                                <li>• Irritasjon, tørrhet eller ømhet i nese, munn eller svelg</li>
                                <li>• Øyeirritasjon, tørrhet, ubehag eller rødhet</li>
                                <li>• Hodepine, svimmelhet</li>
                                <li>• Svakhet, tretthet og skjelving</li>
                                <li>• Angst, frykt, irritabilitet, nervøsitet, rastløs eller ikke sove, forvirret eller se ting</li>
                                <li>• Kvalme, oppkast, mindre spytt enn vanlig i munnen,redusert appetitt</li>
                                <li>• Skylling og synsforstyrrelser</li>
                                <li>• Virkninger på hjertet f.eks. Rask eller uregelmessig hjerterytme, hjertebank</li>
                                <li>• Virkninger på sirkulasjonen f.eks. Kalde føtter eller hender, høyt blodtrykk</li>
                                <li>• Hvis sprayen brukes regelmessig over en lengre periode, kan det forårsake en tilstand som kalles reboundopphopning. Dette er en uvanlig hevelse i neseslimhinnen, som fører til kløe,nysing og blokkert nese etter siste dose av sprayen. Bruk derfor ikkesprayen kontinuerlig i mer enn 7 dager</li>
                                <li>• Dette legemidlet inneholder tiomersal som konserveringsmiddel, og det er mulig at dette kan skjeforårsake lokale hudreaksjoner (f.eks. kontaktdermatitt) og misfarging rundt nesen. Denkan også forårsake en allergisk reaksjon (se ovenfor)</li>
                                <li>• Langvarig og/eller tung bruk utover anbefalt bruk på 7 dager, kan føre tilkardiovaskulære og/eller CNS -effekter.</li>

                            </ul>
                            <p><b>Rapportering av bivirkninger</b></p>
                            <p>Rådfør deg med lege, apotek eller sykepleier hvis du får bivirkninger. Dette inkluderer evtmulige bivirkninger som ikke er nevnt i dette pakningsvedlegget. Du kan også rapportere bivirkninger direkte viaGul kortordning på: <a href="www.mhra.gov.uk/yellowcard"
                                >www.mhra.gov.uk/yellowcard</a> eller søke etter MHRA Yellow Card i Google Play eller Apple App Store. Ved å rapportere bivirkninger kan du hjelpe til med å gi mer informasjon om sikkerheten til dette legemidlet.</p>
                        </div>
                    </text>
                </section>
                <section id="a3776668-4a23-4883-8eec-bd08550da625">
                    <title value="5. Hvordan du oppbevarer Decongestant Nasal Spray"/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="7"/>
                            <display value="5. Hvordan du oppbevarer Decongestant Nasal Spray"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>Ikke bruk dette legemidlet etter utløpsdatoen som er angitt på flasken og esken.</p>
                            <p><b>Oppbevares utilgjengelig for barn.</b></p>
                        </div>
                    </text>
                </section>
                <section id="3cff4c7d-4b8e-4c8a-87fc-2a42224a741d">
                    <title value="6. Innholdet i pakningen og annen informasjon"/>
                    <code>
                        <coding>
                            <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                            <code value="8"/>
                            <display value="6. Innholdet i pakningen og annen informasjon"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p><b>Hva er i denne nesesprayen?</b></p>
                            <br/>
                            <p><b>Den aktive ingrediensen er : </b> Oxymetazoline hydrochloride 0.05% w/v</p>
                            <p><b>Andre ingredienser er: </b> Benzalkoniumklorid, tiomersal, natriumklorid, mentol,eukalyptol, kamfer, metylsalisylat, poloksamer, natriumsitrat, vannfri sitronsyre ogrenset vann.</p>
                            <br/>
                            <p><b>Hvordan dette legemidlet ser ut og innholdet i pakningen</b></p>
                            <p>Produktet er en klar væske som sprayes i fine dråper ut av munnstykketcontainer. En pakke inneholder en hvit 15 ml flaske</p>
                            <br/>
                            <p><b>Innehaver av markedsføringstillatelse:</b></p>
                            <p>Galpharm Healthcare Ltd., Wrafton, Braunton, Devon, EX33 2DL, Storbritannia</p>
                            <p>Produsert for The Boots Company PLC, Nottingham NG2 3AA av<br/>
                                <b>Produsent:</b> Galpharm International Ltd., Elmhirst Park, Middle Field Road, Barnsley,South Yorkshire, S75 4LS, Storbritannia</p>
                            <p>Tekst revidert: september 2020</p>
                            <br/>
                            <p><b>Andre formater</b></p>
                            <p>For å be om en kopi av denne brosjyren i punktskrift, stor skrift eller lyd, ring gratis:</p>
                            <p>0800 198 5000 (bare Storbritannia)</p>
                            <p>Vær klar til å gi følgende informasjon:</p>
                            <p>Produktnavn: Boots Decongestant 0,05% nesespray</p>
                            <p>Referansenummer: PL 16028/0049</p>
                            <p>Dette er en tjeneste som tilbys av Royal National Institute of Blind People.</p>
                        </div>
                    </text>
                </section>
            </Composition>
        </resource>
    </entry>
</Bundle>
